(VIANEWS) – BOIRON (BOI.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| BOIRON (BOI.PA) | €33.62 | 4.12% | 7.15% |
| UCB (UCB.BR) | €141.40 | 0.95% | 3.8% |
| TUBIZE-FIN (TUB.BR) | €112.00 | 0.87% | 4.97% |
| VETOQUINOL (VETO.PA) | €99.50 | 0.86% | 10.98% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. BOIRON (BOI.PA)
4.12% Forward Dividend Yield and 7.15% Return On Equity
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products include medical devices, invitro diagnostics, dietary supplements, cosmetics, and phytotherapy. It also provides homeopathic specialties comprising Oscillococcinum to treat influenza symptoms, such as fever, chills, headaches, and aches; Stodal and Stodaline for treating coughs; Arnigel for adjunctive local treatment of benign trauma in the absence of open wounds; Camilia for the treatment of teething problems for babies; Sédatif PC to treat anxiety and emotional, and minor sleep disorders; Coryzalia for the treatment of cold symptoms and rhinitis; Homéoptic to treat eye discomfort and irritation due to various causes for adults and children; Homéovox for vocal disorders; Homéoplasmine for treating irritated skin and redness; Varésol to treat symptoms of chickenpox; and Arnicare Arthritis for use in the treatment of benign trauma pain. In addition, it offers Dermoplasmine, a plant based multi-use balm that repairs and protects irritated and damaged skin; COVID self-tests and rapid antigenic tests; LABIAMEO, that used to treat outbreaks of localized cold sores; and CONVAMEO to treat physical and mental asthenia. The company offers its products through distribution centers, pharmacies, pharmacy chains, wholesalers, grocery and drugstores, health food stores, and online retail. Boiron SA was founded in 1932 and is headquartered in Messimy, France.
Earnings Per Share
As for profitability, BOIRON has a trailing twelve months EPS of €2.74.
PE Ratio
BOIRON has a trailing twelve months price to earnings ratio of 12.27. Meaning, the purchaser of the share is investing €12.27 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.15%.
More news about BOIRON.
2. UCB (UCB.BR)
0.95% Forward Dividend Yield and 3.8% Return On Equity
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.
Earnings Per Share
As for profitability, UCB has a trailing twelve months EPS of €1.75.
PE Ratio
UCB has a trailing twelve months price to earnings ratio of 80.8. Meaning, the purchaser of the share is investing €80.8 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 3.8%.
Moving Average
UCB’s value is higher than its 50-day moving average of €132.24 and way above its 200-day moving average of €100.41.
Volatility
UCB’s last week, last month’s, and last quarter’s current intraday variation average was a negative 0.72%, a positive 0.11%, and a positive 1.05%.
UCB’s highest amplitude of average volatility was 0.72% (last week), 0.85% (last month), and 1.05% (last quarter).
Yearly Top and Bottom Value
UCB’s stock is valued at €141.40 at 02:30 EST, under its 52-week high of €146.20 and way higher than its 52-week low of €65.40.
Volume
Today’s last reported volume for UCB is 29029 which is 89.17% below its average volume of 268146.
More news about UCB.
3. TUBIZE-FIN (TUB.BR)
0.87% Forward Dividend Yield and 4.97% Return On Equity
Financière de Tubize SA operates as a mono holding company whose sole investment is a stake in UCB which is a biopharma company in Belgium. The company was incorporated in 1928 and is based in Brussels, Belgium.
Earnings Per Share
As for profitability, TUBIZE-FIN has a trailing twelve months EPS of €1.99.
PE Ratio
TUBIZE-FIN has a trailing twelve months price to earnings ratio of 56.28. Meaning, the purchaser of the share is investing €56.28 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.97%.
Moving Average
TUBIZE-FIN’s worth is higher than its 50-day moving average of €102.10 and way above its 200-day moving average of €83.06.
Volume
Today’s last reported volume for TUBIZE-FIN is 1867 which is 89.22% below its average volume of 17327.
More news about TUBIZE-FIN.
4. VETOQUINOL (VETO.PA)
0.86% Forward Dividend Yield and 10.98% Return On Equity
Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
Earnings Per Share
As for profitability, VETOQUINOL has a trailing twelve months EPS of €4.97.
PE Ratio
VETOQUINOL has a trailing twelve months price to earnings ratio of 20.02. Meaning, the purchaser of the share is investing €20.02 for every euro of annual earnings.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.98%.
Volume
Today’s last reported volume for VETOQUINOL is 4463 which is 47.48% above its average volume of 3026.
Moving Average
VETOQUINOL’s worth is above its 50-day moving average of €98.58 and above its 200-day moving average of €96.52.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on Jun 4, 2024, the estimated forward annual dividend rate is 0.85 and the estimated forward annual dividend yield is 0.86%.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, VETOQUINOL’s stock is considered to be oversold (<=20).
More news about VETOQUINOL.
